ARG1 is a potential prognostic marker in metastatic and recurrent endometrial cancer.
Dinh Nam TranValery RozenMark I HunterTae Hoon KimJae-Wook JeongPublished in: Research square (2023)
Endometrial cancer (EC) is the most common gynecologic malignancy. While the majority of patients present with early-stage and low-grade EC and have an excellent prognosis, a subset has metastatic disease at presentation, or develops distant recurrence after initial treatment of the primary. However, the lack of prognostic biomarkers for metastatic EC is a critical barrier. Arginase 1 (ARG1) regulates the last step of the urea cycle, and an increase in ARG1 has been correlated as a poor prognostic factor in a variety of cancers. In the present study, ARG1 expression was evaluated as a potential prognostic marker for metastatic EC in endometrial hyperplasia and cancer of mice with Pten mutation as well as Pten and Mig-6 double mutations. While Pten mutation in the uterus is not sufficient for distant metastasis, mice with concurrent ablation of Mig-6 and Pten develop distant metastasis. Our immunostaining and RT-qPCR analysis revealed that the expression of ARG1 in early stage of EC as well as endometrial hyperplasia from mice deficient in Mig-6 and Pten mutations significantly increased compared to Pten mutation in the uterus. The results suggest that a high level of ARG1 is associated with poor prognosis in association with EC of mouse.
Keyphrases
- endometrial cancer
- poor prognosis
- early stage
- pi k akt
- cell proliferation
- prognostic factors
- low grade
- squamous cell carcinoma
- small cell lung cancer
- long non coding rna
- lymph node
- high fat diet induced
- end stage renal disease
- high grade
- signaling pathway
- chronic kidney disease
- ejection fraction
- newly diagnosed
- wild type
- patient reported outcomes
- peritoneal dialysis
- risk assessment
- human health
- adipose tissue
- neoadjuvant chemotherapy
- case report
- squamous cell
- radiofrequency ablation
- data analysis
- replacement therapy
- free survival
- nitric oxide synthase